Vitamin D may help reduce the risk of colorectal cancer (CRC) by exerting an anti-inflammatory or modulatory effect on biomarkers associated with the disease. While previous studies have investigated individual biomarkers, our approach evaluates their combined effects. We investigated the association between 25-hydroxyvitamin D (25(OH)D) levels, measured using MS, and the expression of 92 inflammatory biomarkers assessed using the Olink Target 96 inflammation panel. This analysis was conducted in women from the Norwegian Women and Health Study (NOWAC), utilising plasma samples taken 1–6 years prior to CRC diagnosis (n = 163) and 163 matched cancer-free controls. Factor analysis was used to identify biomarker patterns, and linear regression examined the association of each factor with 25(OH)D levels. Women with 25(OH)D deficiency (≤30 nmol/L) had significantly higher Factor 1 scores compared to those with sufficient levels (≥50 nmol/L) (β = 0.72, 95% CI: 0.26–1.18). This association was specific to pre-diagnostic CRC cases (β = 0.97, 95% CI: 0.33–1.60) and was not observed in cancer-free controls (β = 0.22, 95% CI: −0.50–0.93). Factor 1 represents a cluster of biomarkers, many of which are pro-inflammatory (TNFSF14, S100-A12, IL-8, IL-18) and many that play key roles in processes such as cell growth, angiogenesis, and apoptosis (OSM, TGF-alpha, VEGF-A, CASP-8). Several of these biomarkers have been independently linked to CRC, exhibiting both unfavourable and favourable roles. The observed association between 25(OH)D deficiency and Factor 1 in pre-diagnostic CRC cases supports the hypothesis that sufficient levels of vitamin D could potentially contribute to prevention of CRC development.